Gelteq (GELS) Competitors $1.56 +0.60 (+62.50%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GELS vs. OTLK, TELO, BRNS, STTK, XFOR, JSPR, NBRV, ANVS, FGEN, and AADIShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Oncobiologics (OTLK), Telomir Pharmaceuticals (TELO), Barinthus Biotherapeutics (BRNS), Shattuck Labs (STTK), X4 Pharmaceuticals (XFOR), Jasper Therapeutics (JSPR), Nabriva Therapeutics (NBRV), Annovis Bio (ANVS), FibroGen (FGEN), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry. Gelteq vs. Its Competitors Oncobiologics Telomir Pharmaceuticals Barinthus Biotherapeutics Shattuck Labs X4 Pharmaceuticals Jasper Therapeutics Nabriva Therapeutics Annovis Bio FibroGen Aadi Bioscience Gelteq (NASDAQ:GELS) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Do institutionals & insiders believe in GELS or OTLK? 11.2% of Oncobiologics shares are held by institutional investors. 4.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is GELS or OTLK more profitable? Company Net Margins Return on Equity Return on Assets GelteqN/A N/A N/A Oncobiologics N/A N/A -332.30% Do analysts recommend GELS or OTLK? Oncobiologics has a consensus target price of $9.60, suggesting a potential upside of 926.74%. Given Oncobiologics' stronger consensus rating and higher probable upside, analysts clearly believe Oncobiologics is more favorable than Gelteq.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oncobiologics 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has stronger valuation and earnings, GELS or OTLK? Gelteq has higher revenue and earnings than Oncobiologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGelteq$100K147.26-$2.33MN/AN/AOncobiologicsN/AN/A-$75.37M-$0.57-1.64 Does the media prefer GELS or OTLK? In the previous week, Oncobiologics had 7 more articles in the media than Gelteq. MarketBeat recorded 9 mentions for Oncobiologics and 2 mentions for Gelteq. Gelteq's average media sentiment score of 0.00 beat Oncobiologics' score of -0.36 indicating that Gelteq is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gelteq 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryOncobiologics beats Gelteq on 6 of the 10 factors compared between the two stocks. Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.73M$3.16B$5.78B$9.92BDividend YieldN/A2.28%6.67%4.52%P/E RatioN/A21.1175.6726.67Price / Sales147.26463.83554.40206.13Price / CashN/A45.1137.1158.92Price / Book1.209.8611.446.09Net Income-$2.33M-$53.47M$3.28B$266.14M7 Day Performance24.60%2.79%0.78%0.22%1 Month Performance-6.02%8.49%7.07%4.08%1 Year PerformanceN/A13.61%59.61%23.89% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$1.56+62.5%N/AN/A$14.73M$100K0.00N/ANews CoverageGap DownHigh Trading VolumeOTLKOncobiologics1.6238 of 5 stars$1.09-54.2%$9.60+780.7%-87.9%$48.42MN/A-1.9120Options VolumeHigh Trading VolumeTELOTelomir Pharmaceuticals3.2513 of 5 stars$1.48flat$15.00+913.5%-73.9%$47.77MN/A-2.741Short Interest ↓High Trading VolumeBRNSBarinthus Biotherapeutics3.622 of 5 stars$1.17+2.6%$3.00+156.4%+3.5%$47.64M$14.97M-0.68107Positive NewsShort Interest ↓Gap DownSTTKShattuck Labs3.6762 of 5 stars$0.99-0.7%$4.00+302.9%-57.7%$47.56M$5.72M-0.82100Positive NewsInsider TradeShort Interest ↑XFORX4 Pharmaceuticals4.2136 of 5 stars$4.12-2.6%$71.17+1,627.3%-82.3%$47.00M$32.77M-0.2880Short Interest ↑Gap UpJSPRJasper Therapeutics2.7968 of 5 stars$2.84-2.1%$28.75+912.3%-86.1%$46.15MN/A-0.4720NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070ANVSAnnovis Bio2.3531 of 5 stars$2.33-0.9%$18.00+672.5%-73.0%$45.41MN/A-1.143Analyst ForecastAnalyst RevisionFGENFibroGen4.1479 of 5 stars$11.13+6.2%$43.00+286.3%+13.2%$45.01M$7.35M-29.29570Gap DownAADIAadi BioscienceN/A$1.81flatN/A+0.6%$44.70M$25.07M-0.7940 Related Companies and Tools Related Companies Oncobiologics Competitors Telomir Pharmaceuticals Competitors Barinthus Biotherapeutics Competitors Shattuck Labs Competitors X4 Pharmaceuticals Competitors Jasper Therapeutics Competitors Nabriva Therapeutics Competitors Annovis Bio Competitors FibroGen Competitors Aadi Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GELS) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
